Saghmos Therapeutics

Saghmos Therapeutics is a privately held biopharmaceuticals company with a Phase 3-ready cardiorenal metabolic modulator ST-62516 (trimetazidine). Saghmos’ IND for ST-62516 was cleared by the FDA in July 2023. ST-62516 is being developed to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as percutaneous coronary intervention (PCI). This is an area of high unmet need. Patients with pre-existing Chronic Kidney Disease (CKD) and comorbidities such as diabetes and heart disease are at high risk of complications, including heart failure and progression of kidney disease, leading to prolonged hospitalization and need for dialysis. There are no approved pharmacologic agents to prevent or treat the problem. Saghmos Therapeutics has an issued US patent providing exclusivity through 2037 for the prevention and treatment of acute kidney injury after contrast procedures.